tbResList Print — MBZ mebendazole

Filters: qv=331, qv2=%, rfv=%

Product

MBZ mebendazole
Description: <b>Mebendazole</b>—an anthelmintic (anti-parasitic) medication<br>
Mebendazole is traditionally used to treat various parasitic worm infections (helminths).<br>
<br>
-Mebendazole has been found to disrupt microtubule formation in cells.<br>
-It might interfere with angiogenesis (the formation of new blood vessels that tumors need to grow)<br>
-Can inhibit the proliferation of various cancer cell lines (such as melanoma, colon cancer, and others)<br>
-May work synergistically with established chemotherapeutic agents.<br>

<p><b>Mebendazole</b> — a synthetic benzimidazole anthelmintic drug with emerging drug-repurposing interest in oncology. It is conventionally used against gastrointestinal helminths and acts pharmacologically through β-tubulin binding and disruption of microtubule assembly. In mammalian cancer models, this same microtubule-targeting activity produces mitotic spindle disruption, G2/M arrest and apoptosis. Standard abbreviations are MBZ and MZ. Mebendazole is FDA-approved as an antiparasitic drug but is not approved as an anticancer therapy. Its oncology development is constrained by extremely poor aqueous solubility, highly variable oral systemic exposure and formulation/polymorph-dependent bioavailability.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>β-tubulin binding and microtubule depolymerization, producing abnormal mitotic spindles and G2/M arrest.</li>
<li>Intrinsic apoptotic signaling with mitochondrial dysfunction, cytochrome-c release and caspase activation.</li>
<li>Suppression of angiogenesis and hypoxic adaptation, including VEGF and HIF-1α/HIF-2α signaling in responsive models.</li>
<li>ROS elevation with downstream JAK2/STAT3 suppression in some tumor types.</li>
<li>Hedgehog pathway inhibition through disruption of primary-cilium-dependent signaling.</li>
<li>Interference with DNA-damage-response trafficking and consequent radiosensitization.</li>
<li>Context-dependent inhibition of oncogenic kinase signaling, including BRAF/MEK/ERK-related signaling.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Oral bioavailability is low and highly variable because mebendazole is poorly water-soluble and undergoes substantial first-pass disposition. Systemic exposure can increase with food, particularly a fatty meal. Crystal polymorphism is important: polymorph C generally has superior dissolution and pharmaceutical performance compared with polymorph A, while formulations designed to improve solubility can substantially increase exposure. These PK limitations are particularly important for oncology because sustained systemic exposure is required, unlike treatment of many intestinal helminth infections.<br>
-bioavailability improves when taken with high fat meal
</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many cancer-cell effects occur at submicromolar to low-micromolar concentrations, including tubulin disruption and apoptosis. Such concentrations may be approached in some high-dose or optimized-formulation settings, but systemic exposure after conventional antiparasitic dosing is variable and generally much lower and less predictable. Therefore, anticancer activity demonstrated in vitro should not be assumed to occur with standard antiparasitic dosing. Formulation, food intake, polymorph, dose and interpatient PK variability are major translational variables.<br>
-Mebendazole presents a substantially greater documented toxicity concern for the liver than for the kidneys, particularly when used at the high doses and prolonged durations investigated for cancer treatment.
</p>

<p><b>Clinical evidence status:</b> Predominantly preclinical with early human oncology evidence. Phase I studies in adult and pediatric high-grade glioma demonstrate feasibility of substantially higher and prolonged dosing than standard anthelmintic treatment, with hepatic and hematologic toxicity becoming relevant at high exposure. A small randomized placebo-controlled study in metastatic colorectal cancer reported improved response and progression-free survival when mebendazole was added to bevacizumab/FOLFOX4, but the study enrolled only 40 patients and requires independent confirmation. A randomized phase II recurrent-glioblastoma study combining mebendazole with temozolomide or lomustine did not reach its predefined efficacy benchmark. Mebendazole should therefore be classified as an investigational repurposed anticancer adjunct rather than an established cancer therapy.</p>


<h3>Mebendazole Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>β-Tubulin and Microtubule Dynamics</td>
<td>β-tubulin targeting; microtubule polymerization ↓</td>
<td>Microtubules can also be affected; generally lower sensitivity reported in some comparative models</td>
<td>P/R/G</td>
<td>Mitotic spindle disruption and proliferation ↓</td>
<td>Best-established and most mechanistically central anticancer action of mebendazole. Provides the mechanistic bridge between its anthelmintic and anticancer activities.</td>
</tr>
<tr>
<td>2</td>
<td>G2/M Cell-Cycle Arrest</td>
<td>G2/M arrest ↑</td>
<td>Less pronounced in some nonmalignant-cell comparisons</td>
<td>R/G</td>
<td>Mitotic progression ↓</td>
<td>Closely downstream of microtubule disruption and commonly precedes apoptotic cell death.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial Apoptosis</td>
<td>Mitochondrial permeability ↑; cytochrome-c release ↑; caspase-3 activation ↑</td>
<td>Lower apoptosis reported in several nonmalignant-cell comparisons</td>
<td>R/G</td>
<td>Apoptosis ↑</td>
<td>Strongly supported downstream consequence of spindle disruption; apoptosis may also involve additional stress pathways.</td>
</tr>
<tr>
<td>4</td>
<td>Angiogenesis and VEGF</td>
<td>VEGF ↓; tumor vascularization ↓</td>
<td>Context-dependent</td>
<td>G</td>
<td>Angiogenesis ↓</td>
<td>Supported by xenograft studies and by decreased VEGF in the small metastatic colorectal cancer randomized trial.</td>
</tr>
<tr>
<td>5</td>
<td>Hypoxia HIF Signaling</td>
<td>HIF-1α activity ↓; HIF-2α activity ↓</td>
<td>Not well characterized</td>
<td>R/G</td>
<td>Hypoxic adaptation ↓</td>
<td>Demonstrated particularly in breast-cancer models. Likely contributes to antiangiogenic and metabolic effects but is not the universal primary mechanism.</td>
</tr>
<tr>
<td>6</td>
<td>ROS JAK2 STAT3 Signaling</td>
<td>ROS ↑; JAK2/STAT3 signaling ↓</td>
<td>Context-dependent</td>
<td>R/G</td>
<td>Survival signaling ↓; apoptosis ↑; migration ↓</td>
<td>Well demonstrated in NSCLC models, including reversal of effects by ROS scavenging. Best considered tumor- and model-dependent rather than a universal MBZ mechanism.</td>
</tr>
<tr>
<td>7</td>
<td>Hedgehog and Primary Cilium</td>
<td>Primary cilium formation ↓; Hedgehog signaling ↓</td>
<td>Potential effects in ciliated normal cells not adequately defined for oncology exposure</td>
<td>R/G</td>
<td>Hedgehog-dependent proliferation ↓</td>
<td>Potentially important in Hedgehog-driven tumors such as subsets of medulloblastoma. Mechanistically linked to microtubule-dependent primary-cilium formation.</td>
</tr>
<tr>
<td>8</td>
<td>DNA Damage Response and Radiosensitization</td>
<td>Nuclear trafficking of Chk2/Nbs1 ↓; persistent γH2AX ↑; radiosensitivity ↑</td>
<td>Not sufficiently established</td>
<td>R/G</td>
<td>DNA repair efficiency ↓; radiation response ↑</td>
<td>Mebendazole can radiosensitize glioma and breast-cancer models. This can occur independently of mitotic arrest through microtubule-dependent trafficking of DNA-damage-response proteins.</td>
</tr>
<tr>
<td>9</td>
<td>BRAF MEK ERK Signaling</td>
<td>BRAF activity ↓; MEK/ERK phosphorylation ↓ (context-dependent)</td>
<td>Not well characterized</td>
<td>P/R</td>
<td>MAPK survival signaling ↓</td>
<td>Relevant particularly in selected melanoma models and combination with MEK inhibition. Not sufficiently general to rank with tubulin disruption.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization</td>
<td>Response to selected cytotoxic or targeted agents ↑ (context-dependent)</td>
<td>Combination toxicity is treatment-dependent</td>
<td>G</td>
<td>Combination anticancer activity ↑</td>
<td>Preclinical synergy has been reported with several agents; a small human colorectal trial reported improved response when added to bevacizumab/FOLFOX4. Evidence is not yet sufficient to establish a general clinical chemosensitizer indication.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Exposure highly variable; effective tumor concentrations uncertain</td>
<td>High-dose prolonged treatment can cause hepatotoxicity, neutropenia and agranulocytosis</td>
<td>G</td>
<td>Clinical translation limited</td>
<td>Very poor aqueous solubility, polymorph-dependent dissolution, substantial first-pass disposition and variable absorption complicate oncology dosing. Fat-containing meals can increase systemic exposure. High-dose/prolonged use requires safety monitoring; concomitant metronidazole should be avoided because of reported severe skin reactions.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

ENOX2↓, 1,   ROS↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 14,   Bcl-2?, 1,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 5,   cl‑Casp3↑, 2,   Casp7↑, 1,   Cyt‑c↑, 3,   MOMP↑, 1,   TumCD↑, 2,   XIAP↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt?, 1,   BRAF↓, 2,   DYRK1B↓, 1,   EGFR↓, 1,   p‑ERK↓, 1,   p‑JAK2↓, 1,   p‑MEK↓, 1,   MEK↓, 1,   PI3K?, 1,   PKA↓, 1,   RCC1↓, 1,   p‑STAT3↓, 1,   STAT4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ARNT?, 1,   cMyc↓, 2,   METTL7A↑, 1,   other↝, 3,   RASSF1A↑, 1,   tumCV↓, 3,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 3,   P53↑, 2,   cl‑PARP↑, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

Ki-67↓, 1,   mitA↑, 3,   P21↑, 2,   p27/CDKN1B↑, 1,   TubPol↓, 3,   TumCCA↑, 8,   TumCCA?, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   Gli1↓, 2,   HH↓, 2,   Ki-67↓, 1,   PTCH1↓, 1,   PTCH2↓, 1,   Shh↓, 1,   Smo↓, 1,   TumCG↓, 5,   TumCG?, 2,   TumCP↓, 7,  

Migration(tgid=13) ⓘ

EMT↓, 1,   ITGB4↓, 1,   MMP2↓, 2,   MMPs↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumCMig↓, 3,   TumMeta↓, 2,   TumMeta?, 1,   Twist↓, 1,   α-tubulin↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   Hif1a↓, 2,   HIF2a↓, 1,   VCAM-1↓, 1,   VEGF↓, 3,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   EPR↑, 1,   GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IFN-γ↓, 1,   IL1β↓, 1,   IL6↓, 1,   TNF-α↑, 1,   WFDC10A↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

SYN1↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ARNT?, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 4,   ChemoSen↑, 3,   ChemoSen?, 1,   Dose↝, 7,   Dose?, 1,   eff↓, 2,   eff↑, 4,   eff∅, 1,   Half-Life↝, 1,   Half-Life↑, 1,   MDR1↓, 1,   RadioS↑, 4,   RadioS?, 1,   selectivity↑, 4,   Synergy↑, 9,  

Clinical Biomarkers(tgid=22) ⓘ

BRAF↓, 2,   EGFR↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 2,   chemoPv↑, 1,   OS↑, 4,   OS?, 1,   PFS↑, 1,   QoL↑, 1,   toxicity↓, 2,   toxicity↝, 2,   TumVol↓, 3,   TumW↓, 1,  
Total Targets: 114

Pathway results for Effect on Normal Cells

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 3,  
Total Targets: 1

Research papers

Year Title Authors PMID Link Flag
2026Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatmentRaed M Al-Zoubi42217373https://pubmed.ncbi.nlm.nih.gov/42217373/0
2026Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7ARasha Shaker AqelPMC13020803https://pmc.ncbi.nlm.nih.gov/articles/PMC13020803/0
2025The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline gliomaSerena GentilePMC12256405https://pmc.ncbi.nlm.nih.gov/articles/PMC12256405/0
2025Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumorsPaul PhanPMC12741831https://pmc.ncbi.nlm.nih.gov/articles/PMC12741831/0
2025Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer Cell linesMohamed El-TananiPMC12707669https://pmc.ncbi.nlm.nih.gov/articles/PMC12707669/0
2024Mebendazole induces apoptosis and inhibits migration via the reactive oxygen species-mediated STAT3 signaling downregulation in non-small cell lung cancerZhipan LiangPMC10944755https://pmc.ncbi.nlm.nih.gov/articles/PMC10944755/0
2024In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioningAmin Aliabadi37837472https://pubmed.ncbi.nlm.nih.gov/37837472/0
2023Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer CellsNatalie S JoePMC9954103https://pmc.ncbi.nlm.nih.gov/articles/PMC9954103/0
2022Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ionYusuke Sumimoto35134511https://pubmed.ncbi.nlm.nih.gov/35134511/0
2022HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In VivoMartin StudenovskýPMC9229042https://pmc.ncbi.nlm.nih.gov/articles/PMC9229042/0
2022The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal CancerBo KangPMC9737525https://pmc.ncbi.nlm.nih.gov/articles/PMC9737525/0
2022Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancerSahar K Hegazy35385794https://pubmed.ncbi.nlm.nih.gov/35385794/0
2022Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemnessNatalie S JoePMC9798635https://pmc.ncbi.nlm.nih.gov/articles/PMC9798635/0
2022Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancerSuganthapriya ElayapillaiPMC8820236https://pmc.ncbi.nlm.nih.gov/articles/PMC8820236/0
2021Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell deathJakeb S S M PetersenPMC11802096https://pmc.ncbi.nlm.nih.gov/articles/PMC11802096/0
2020The Antihelminthic Drug, Mebendazole, Induces Apoptosis in Adult T-Cell Leukemia/Lymphoma Cancer Cells: In-Vitro TrialAmirhosein MaaliPMC7876428https://pmc.ncbi.nlm.nih.gov/articles/PMC7876428/0
2020Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast CancerLe ZhangPMC6457649https://pmc.ncbi.nlm.nih.gov/articles/PMC6457649/0
2019Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current LiteratureAndrea Emanuele GueriniPMC6769799https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/0
2019Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01)Laine Celestino Pinto31207347https://pubmed.ncbi.nlm.nih.gov/31207347/0
2019Autophagy Is a Potential Target for Enhancing the Anti-Angiogenic Effect of Mebendazole in Endothelial CellsSo Jung SungPMC6319545https://pmc.ncbi.nlm.nih.gov/articles/PMC6319545/0
2018Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningiomaChristine G SkibinskiPMC6387633https://pmc.ncbi.nlm.nih.gov/articles/PMC6387633/0
2017Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain TumorsMichelle De WittPMC5403762https://pmc.ncbi.nlm.nih.gov/articles/PMC5403762/0
2017Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)Fugui ZhangPMC5355070https://pmc.ncbi.nlm.nih.gov/articles/PMC5355070/0
2017The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanomaCynthia M Simbulan-RosenthalPMC5355037https://pmc.ncbi.nlm.nih.gov/articles/PMC5355037/0
2017Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanismDaniel MarkowitzPMC5703169https://pmc.ncbi.nlm.nih.gov/articles/PMC5703169/0
2016Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical modelTara WilliamsonPMC5356574https://pmc.ncbi.nlm.nih.gov/articles/PMC5356574/0
2016Repurposing the antihelmintic mebendazole as a hedgehog inhibitorAndrew R LarsenPMC4297232https://pmc.ncbi.nlm.nih.gov/articles/PMC4297232/0
2011Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiformeRen-Yuan BaiPMC3158014https://pmc.ncbi.nlm.nih.gov/articles/PMC3158014/0
2008Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cellsNicole Doudican18667591https://pubmed.ncbi.nlm.nih.gov/18667591/0
2002Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivoTapas Mukhopadhyay12231542https://pubmed.ncbi.nlm.nih.gov/12231542/0
2002The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cellsJi-ichiro Sasaki12479701https://pubmed.ncbi.nlm.nih.gov/12479701/0